Hypertension in African populations: review and computational insights
Hypertension (HTN) is a persistent public health problem affecting approximately 1.3 billion
individuals globally. Treatment-resistant hypertension (TRH) is defined as high blood …
individuals globally. Treatment-resistant hypertension (TRH) is defined as high blood …
Pharmacogenomics of Hypertension in Africa: Paving the Way for a Pharmacogenetic‐Based Approach for the Treatment of Hypertension in Africans
JN Katsukunya, ND Soko, J Naidoo… - International Journal …, 2023 - Wiley Online Library
In Africa, the burden of hypertension has been rising at an alarming rate for the last two
decades and is a major cause for cardiovascular disease (CVD) mortality and morbidity …
decades and is a major cause for cardiovascular disease (CVD) mortality and morbidity …
Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension
F Rahman, N Muthaiah… - Indian Journal of …, 2021 - journals.lww.com
Hypertension is a leading age-related disease in our society and if left untreated, leads to
fatal cardiovascular complications. The prevalence of hypertension has increased and …
fatal cardiovascular complications. The prevalence of hypertension has increased and …
Pharmacogenomics of hypertension treatment
J Rysz, B Franczyk, M Rysz-Górzyńska… - International journal of …, 2020 - mdpi.com
Hypertension is one of the strongest modifiable cardiovascular risk factors, affecting an
increasing number of people worldwide. Apart from poor medication adherence, the low …
increasing number of people worldwide. Apart from poor medication adherence, the low …
Computational and pharmacogenomic insights on hypertension treatment: rational drug design and optimization strategies
L Loganathan, K Gopinath… - Current Drug …, 2020 - ingentaconnect.com
Background: Hypertension is a prevalent cardiovascular complication caused by genetic
and nongenetic factors. Blood pressure (BP) management is difficult because most patients …
and nongenetic factors. Blood pressure (BP) management is difficult because most patients …
The pharmacogenomics of anti-hypertensive therapy
S Padmanabhan, L Paul, AF Dominczak - Pharmaceuticals, 2010 - mdpi.com
Hypertension is a major public health problem, but measures to reduce blood pressure and
thus cardiovascular risk are complicated by the high prevalence of treatment resistance …
thus cardiovascular risk are complicated by the high prevalence of treatment resistance …
Pharmacogenomics and hypertension: current insights
GH Oliveira-Paula, SC Pereira… - Pharmacogenomics …, 2019 - Taylor & Francis
Hypertension is a multifactorial disease that affects approximately one billion subjects
worldwide and is a major risk factor associated with cardiovascular events, including …
worldwide and is a major risk factor associated with cardiovascular events, including …
Hypertension pharmacogenomics: in search of personalized treatment approaches
RM Cooper-DeHoff, JA Johnson - Nature Reviews Nephrology, 2016 - nature.com
Cardiovascular and renal diseases are associated with many risk factors, of which
hypertension is one of the most prevalent. Worldwide, blood pressure control is only …
hypertension is one of the most prevalent. Worldwide, blood pressure control is only …
Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment
MT Eadon, SH Kanuri, AB Chapman - Expert review of precision …, 2018 - Taylor & Francis
Introduction: Increasing clinical evidence supports the implementation of genotyping for anti-
hypertensive drug dosing and selection. Despite robust evidence gleaned from clinical trials …
hypertensive drug dosing and selection. Despite robust evidence gleaned from clinical trials …
Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy
EF Magavern, V Kapil, M Saxena, A Gupta… - … and Vascular Biology, 2024 - Am Heart Assoc
Hypertension is a prevalent public health problem, contributing to> 10 million deaths
annually. Though multiple therapeutics exist, many patients suffer from treatment-resistant …
annually. Though multiple therapeutics exist, many patients suffer from treatment-resistant …